Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people notice increased hair shedding a few months after starting weight loss injections — it is one of the most common concerns raised during consultations, and understandably so. The short answer is that this shedding is real, usually temporary, and in most cases linked to rapid caloric deficit rather than the medicine itself. These are prescription-only treatments assessed individually by a clinician, and your prescriber is the right person to discuss how this risk applies to your situation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people who contact their prescriber about hair loss during treatment share a similar story: weight has been coming off steadily, things are going well, and then (usually around the three-month mark) the shower drain tells a different story. This is telogen effluvium, and it happens when the body experiences a significant physiological stress. Rapid weight loss, regardless of how it is achieved, counts as that kind of stress.
During normal hair growth, roughly 85–90% of hairs are in the active (anagen) phase at any one time. A nutritional shock or sudden caloric change can push a larger than normal proportion into the resting (telogen) phase simultaneously. Two to four months later, those hairs shed at once. The timing can make it feel as though the injection is to blame, even when the underlying trigger was the caloric deficit.
The NHS patient information on tirzepatide lists hair loss as a recognised side effect. Semaglutide trials have shown a similar pattern. The distinction (between drug-direct effect and caloric-deficit effect) matters less in practice than managing nutrition during treatment. Protein adequacy is the key variable: our prescribers at nume consistently flag adequate daily protein intake as part of the broader lifestyle guidance that runs alongside treatment.
The shedding usually peaks, then slows. Regrowth follows in the months after the body stabilises. That said, this is a general pattern, not a guarantee, individual variation is real.
Telogen effluvium is diffuse. If what you are seeing is patchy, if you are losing eyebrows or body hair alongside scalp hair, or if shedding is severe rather than simply noticeable, something else may be going on. Thyroid dysfunction, iron deficiency anaemia and other conditions can be unmasked or worsened during periods of significant dietary change, and they can also independently cause hair loss.
Anyone who is finding that hair loss and weight loss injections seem to be closely linked in their experience (particularly if shedding is accelerating rather than stabilising) should speak to their GP. Blood tests to check ferritin, thyroid function and nutritional markers are a sensible first step. A dermatologist referral may follow if there is any suggestion of alopecia areata or another condition separate from telogen effluvium.
From a medicines-safety perspective, if you experience any unexpected or significant side effect you can report it directly to the MHRA through the Yellow Card scheme. That reporting genuinely contributes to post-market surveillance; it is not just a formality.
Some people also ask whether other injection-based wellness products marketed alongside weight management (sometimes called NAD injections) carry their own considerations. Those are distinct from licensed GLP-1 medicines; our overview of NAD injections and weight loss covers them separately.
There is no single fix, but the following are consistently supported by clinical guidance:
Keep protein intake up. Aim for an adequate daily protein target, what that means for you specifically is a conversation for your prescriber or a dietitian, not a fixed number on a webpage. When appetite is suppressed by GLP-1 treatment, getting protein-dense foods in first at each meal tends to help.
Slow, steady loss is gentler on the body than a sharp drop. Dose titration in GLP-1 treatment is already designed to be gradual; avoiding additional aggressive caloric restriction on top of the medicine's natural appetite effects is sensible practice.
Check for nutritional gaps. Iron, zinc, biotin and B vitamins all play a role in hair growth. It is also worth being aware that bone density can be affected by weight loss injections, so a basic blood panel around six to eight weeks into treatment is a reasonable baseline, especially if periods have become heavier or dietary variety has fallen.
If you are due for a review and realise you have been on the same dose since before a bank holiday (it happens, orders placed around a long weekend can shift review timings), the contact team can help you get back on schedule. Consistency matters for both weight outcomes and nutritional stability.
A question our prescribers hear regularly is whether hair shedding means treatment should stop. The honest answer is: rarely, and only after ruling out other causes. Telogen effluvium that is progressing predictably (shedding for two to four months then slowing) does not normally require stopping a medicine that is working well for someone's health.
What it does require is proper nutritional support and monitoring. People living with certain neurological conditions may also want to read about how MS and weight loss injections interact before their first pen arrives, and the same applies to reading about how hair loss relates to weight loss injections more broadly to help frame expectations.
At a free consultation with our prescribers, side effects including the possibility of hair shedding are discussed as part of the clinical assessment, not glossed over afterwards. A named, GPhC-registered prescriber reads your answers and assesses suitability, a real clinician, not an automated decision. If this concern is something you want to address upfront, it is exactly the kind of thing the consultation is for.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.